Normal ambulatory blood pressure in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy

Author(s)

Juliano Henrique Borges ^[1] ; Daniela Albiero Camargo ^[2] ; Leticia Esposito Sewaybricker ^[3] ; Renata Isa Santoro ^[4] ; Daniel Minutti de Oliveira ^[5] ; Sofia Helena Valente de Lemos-Marini ^[6] ; Bruno Geloneze ^[7] ; Gil Guerra-Júnior ^[8] ; Ezequiel Moreira Gonçalves ^[9]

Affiliation

^[1] Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Centro de Investigação em Pediatria - Brasil

^[2] Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Centro de Investigação em Pediatria - Brasil

^[3] Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Centro de Investigação em Pediatria - Brasil

^[4] Unicamp. FCM. Departamento de Pediatria - Brasil

^[5] Unicamp. FCM. Laboratório de Investigação em Metabolismo e Diabetes (LIMED) - Brasil

^[6] Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Centro de Investigação em Pediatria - Brasil

^[7] Unicamp. FCM. Laboratório de Investigação em Metabolismo e Diabetes (LIMED) - Brasil

^[8] Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Centro de Investigação em Pediatria - Brasil

^[9] Universidade Estadual de Campinas. Faculdade de Ciências Médicas. Centro de Investigação em Pediatria - Brasil

• Document type: Journal article
• Source: ARCHIVES OF ENDOCRINOLOGY METABOLISM; 2022-08-12.

Abstract

ABSTRACT Objective: Herein, we compared ambulatory blood pressure (ABP) between young adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase enzyme (21OHase) deficiency and a control group. Additionally, we analyzed correlations between the glucocorticoid dose and androgen levels and ABP parameters. Subjects and methods: This case-control study included 18 patients (6 males and 12 females) and 19 controls (8 males and 11 females) matched by age (18-31 years). ABP monitoring was used to estimate blood pressure (BP) over a 24-h period. Results: No difference was noted between patients and controls in terms of systolic BP (males, 115.5 ± 5.6 vs. 117.0 ± 9.3, P = 0.733; and females, 106.4 ± 7.9 vs. 108.4 ± 7.6, P = 0.556, respectively) and diastolic BP during 24 h (males, 62.8 ± 7.5 vs. 66.2 ± 5.6, P = 0.349; and females, 62.7 ± 4.9 vs. 62.3 ± 4.9, P = 0.818, respectively). Systolic and diastolic BP and pulse pressure during daytime and nocturnal periods were similar between patients and controls. Furthermore, no differences were detected in the percentage of load and impaired nocturnal dipping of systolic and diastolic BP between patients and controls during the 24-h period. Additionally, the glucocorticoid dose (varying between r = −0.24 to 0.13, P > 0.05) and androgens levels (varying between r = 0.01 to 0.14, P > 0.05) were not associated with ABP parameters. Conclusion: No signs of an elevated risk for hypertension were observed based on ABP monitoring in young adults with CAH attributed to 21OHase deficiency undergoing glucocorticoid replacement therapy. (AU)

• FAPESP's process: 11/23460-1 - Cardiometabolic risk in patients with classical Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency.
• Grantee: Ezequiel Moreira Gonçalves
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• FAPESP's process: 12/16778-8 - Cardiometabolic evaluation and pancreatic beta cell secretion pattern in congenital adrenal hyperplasia patients
• Grantee: Gil Guerra Júnior
• Support Opportunities: Regular Research Grants
• FAPESP's process: 17/00657-0 - Impact of obesity-associated diabetes mellitus on the development of hypothalamic gliosis in adolescents
• Grantee: Leticia Esposito Sewaybricker
• Support Opportunities: Scholarships abroad - Research
• FAPESP's process: 14/20186-4 - Relationship between blood pressure and body fat in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
• Grantee: Daniela Albiero Camargo
• Support Opportunities: Scholarships in Brazil - Scientific Initiation